Connect with us

China

Human Infection of H3N8 Bird Flu Reported in China

Published

on

coronavirus covid 19

Will it ever end? On Tuesday this week China’s health authority recorded its first human infection of the H3N8 strain of avian influenza. The variant was identified in a 4-year-old boy from Henan province.

According to a statement from the National Health Commission (NHC) the child raises chickens and crows in his home city of Zhumadian. On April 5 he showed fever and other symptoms, then was admitted to a medical institution five days later for treatment.

The statement indicated while it has been found in horses, dogs, birds and seals around the world, no human cases have ever been reported. Fox News reports the commission “warned the public to avoid contact with sick and dead poultry, as well as live poultry, and pay attention to hygiene.”

In March, the U.S. Centers for Disease Control and Prevention (CDC) wrote highly pathogenic avian influenza viruses had been detected in 13 states among commercial and backyard poultry, as well as in wild birds of 14 states.

Fortunately, the agency said H5N1 bird flu poses a low risk to the public.

 

You may like

Continue Reading
4 Comments

4 Comments

  1. JBnID

    April 29, 2022 at 5:35 pm

    Do you really expect us to worry about health news coming from China?

  2. Steve

    April 30, 2022 at 10:06 am

    Interesting that most animal
    To human virus transfers happen in China. I don’t imagine gain-of-function research has anything to do with it.

  3. S A G

    April 30, 2022 at 10:08 am

    Coming to a town near YOU…

  4. Stephane

    May 6, 2022 at 4:58 am

    Thank you FAUX-XI!

Leave a Reply

Your email address will not be published. Required fields are marked *

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

on

FinalFDAshutterstock 1044596995

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.

 

You may like

Continue Reading
Advertisement
-->

Trending Now

Advertisement
-->

Trending